Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2011 Sep 26:749–782. [Article in German] doi: 10.1007/978-3-642-14223-9_38

Portale Hypertension

J Bauer 4, P-A Clavien 5, P Dutkowski 5, WA Gantert 6, G Lurje 5, B Müllhaupt 7, EL Renner 8, M Schmeding 9, M Selzner 10, M von Flüe 11, C Sieber
Editors: Jörg Rüdiger Siewert1, Matthias Rothmund2, Volker Schumpelick3
PMCID: PMC7123479

Zusammenfassung

Während die Pathologie, die zur portalen Hypertension führt, im prähepatischen, hepatischen und posthepatischen venösen Gefäßbett liegen kann, machen die intrahepatischen Erkrankungen mit Abstand den Großteil aus. In unseren Breitengraden ist es die durch Alkoholabusus bedingte ethyltoxische Leberzirrhose, weltweit die durch Infektionen (HCV, HBV) bedingten Zirrhosen. Die chronische Hepatitis C mit ihren Komplikationen (Leberzellversagen, portale Hypertension und hepatozelluläres Karzinom) wird in den kommenden Jahren trotz moderner Therapieverfahren noch an Bedeutung gewinnen.

Literatur

38.1.6 Literatur

  1. Als-Nielsen B, Gluud LL, Gluud C, et al. Dopaminergic agonists for hepatic encephalopathy. Cochrane Database Syst Rev. 2004;18:CD003047. doi: 10.1002/14651858.CD003047.pub2. [DOI] [PubMed] [Google Scholar]
  2. Ballet F, Chretien Y, Rey C, et al. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther. 1988;244:233–235. [PubMed] [Google Scholar]
  3. Blei AT, Cordoba J, et al. Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968–1976. doi: 10.1111/j.1572-0241.2001.03964.x. [DOI] [PubMed] [Google Scholar]
  4. Butterworth RF, et al. Hepatic encephalopathy – a serious complication of alcoholic liver diesease. Alcohol Res Health. 2003;27:143–145. [PMC free article] [PubMed] [Google Scholar]
  5. Graupera M, Garcia-Pagan JC, Titos E, et al. 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat liver: a possible role of cysteinyl-leukotrienes. Gastroenterology. 2002;122:387–393. doi: 10.1053/gast.2002.31040. [DOI] [PubMed] [Google Scholar]
  6. Gupta TK, Toruner M, Chung MK, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28:926–931. doi: 10.1002/hep.510280405. [DOI] [PubMed] [Google Scholar]
  7. Kundra A, Jain A, Banga A, et al. Evaluation of plasma ammonia levels in patients with acute liver failure and chornic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem. 2005;38:696–699. doi: 10.1016/j.clinbiochem.2005.04.013. [DOI] [PubMed] [Google Scholar]
  8. Lockwood AH, et al. Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis. 2004;19:345–349. doi: 10.1023/b:mebr.0000043980.74574.eb. [DOI] [PubMed] [Google Scholar]
  9. Marteau P, Ballet F, Chazouilleres O, et al. Effect of vasodilators on hepatic microcirculation in cirrhosis : a study in the isolated perfused rat liver. Hepatology. 1989;9:820–823. doi: 10.1002/hep.1840090605. [DOI] [PubMed] [Google Scholar]
  10. Pinzani M, Gentilini P, et al. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis. 1999;19:397–410. doi: 10.1055/s-2007-1007128. [DOI] [PubMed] [Google Scholar]
  11. Reichen J, Le M, et al. Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J Clin Invest. 1986;78:448–455. doi: 10.1172/JCI112596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rockey DC, Weisiger RA, et al. Endothelial induced contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance. Hepatology. 1996;24:233–240. doi: 10.1002/hep.510240137. [DOI] [PubMed] [Google Scholar]
  13. Rockey DN, Chung JJ, et al. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension. Gastroenterology. 1998;114:344–351. doi: 10.1016/s0016-5085(98)70487-1. [DOI] [PubMed] [Google Scholar]
  14. Sieber CC, Stalder GA, et al. Pathophysiologische und pharmakotherapeutische Aspekte der portalen Hypertonie. Schw Med Wschr. 1993;123:3–13. [PubMed] [Google Scholar]
  15. Wiest R, Groszmann RJ, et al. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. Hepatology. 2002;35:478–491. doi: 10.1053/jhep.2002.31432. [DOI] [PubMed] [Google Scholar]

38.2.9 Literatur

  1. Abraldes JG, Villanueva C, Banares R, Aracil C, Catalina MV, Garci APJC, Bosch J, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol. 2008;48:229–36. doi: 10.1016/j.jhep.2007.10.008. [DOI] [PubMed] [Google Scholar]
  2. Avgerinos A, Rekoumis G, Klonis C, Papadimitriou N, Gouma P, Pournaras S, Raptis S, et al. Propanolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscpic sclerotherapy. J Hepatol. 1993;19:301–311. doi: 10.1016/s0168-8278(05)80586-0. [DOI] [PubMed] [Google Scholar]
  3. Avgerinos A, Armonis A, Raptis S, et al. Somatostatin and octreotide in the management of acute variceal bleeding. Hepatogastroenterology. 1995;42:145–150. [PubMed] [Google Scholar]
  4. Bambha K, Kim WR, Pedersen R, Bida JP, Kremers WK, Kamath PS, et al. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut. 2008;57:814–20. doi: 10.1136/gut.2007.137489. [DOI] [PubMed] [Google Scholar]
  5. Bernard B, Grange J, Nyugen K, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis. Hepatology. 1999;29:1655–1661. doi: 10.1002/hep.510290608. [DOI] [PubMed] [Google Scholar]
  6. Bhasin D, Siyad I, et al. Variceal bleeding and portal hypertension: New lights on old horizon. Endoscopy. 2004;36:120–129. doi: 10.1055/s-2004-814179. [DOI] [PubMed] [Google Scholar]
  7. Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, D’Amico G, Lebrec D, de Franchis R, Fabricius S, Cai Y, Bendtsen F, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology. 2008;47:1604–1614. doi: 10.1002/hep.22216. [DOI] [PubMed] [Google Scholar]
  8. Bureau C, Peron J, Alric L, et al. »A la carte« treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology. 2002;36:1361–1366. doi: 10.1053/jhep.2002.36945. [DOI] [PubMed] [Google Scholar]
  9. Cales P, Masliah C, Bernard B, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med. 2001;344:23–28. doi: 10.1056/NEJM200101043440104. [DOI] [PubMed] [Google Scholar]
  10. Casado M, Bosch J, Garcia-Pagan J, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology. 1998;114:1296–1303. doi: 10.1016/s0016-5085(98)70436-6. [DOI] [PubMed] [Google Scholar]
  11. Chau T, Patch D, Chan Y, et al. Salvage transjugular intrahepatic portosystemic shunts: Gastric fundal compared with esophageal variceal. Gastroenterology. 1998;114:981–987. doi: 10.1016/s0016-5085(98)00640-4. [DOI] [PubMed] [Google Scholar]
  12. Cipolletta L, Zambelli A, Bianco MA, De Grazia F, Meucci C, Lupinacci G, Salerno R, Piscopo R, Marmo R, Orsini L, Rotondano G, et al. Acrylate glue injection for acutely bleeding oesophageal varices: A prospective cohort study. Dig Liver Dis. 2009;41:729–734. doi: 10.1016/j.dld.2009.02.006. [DOI] [PubMed] [Google Scholar]
  13. D’Amico G, Garcia-Pagan JC, Luca A, Bosch J, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131:1611–24. doi: 10.1053/j.gastro.2006.09.013. [DOI] [PubMed] [Google Scholar]
  14. Dell’Era A, de Franchis R, Iannuzzi F, et al. Acute variceal bleeding: pharmacological treatment and primary/secondary prophylaxis. Best Pract Res Clin Gastroenterol. 2008;22:279–294. doi: 10.1016/j.bpg.2007.11.001. [DOI] [PubMed] [Google Scholar]
  15. Frossard J, Spahr L, Queneau P, et al. Erythromycin venous bolus infusion in acute upper gastrointestinal bleeding: A randomized, controlled, double-blind trial. Gastroenterology. 2002;123:17–23. doi: 10.1053/gast.2002.34230. [DOI] [PubMed] [Google Scholar]
  16. Garcia-Tsao G, et al. Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology. 2002;120:726–748. doi: 10.1053/gast.2001.22580. [DOI] [PubMed] [Google Scholar]
  17. Gross M, Schiemann U, Muhlhofer A, Zoller W, et al. Meta-analysis: efficacy of therapeutic regimens in ongoing variceal bleeding. Endoscopy. 2001;33:737–746. doi: 10.1055/s-2001-16526. [DOI] [PubMed] [Google Scholar]
  18. Henderson JM, Boyer TD, Kutner MH, Galloway JR, Rikkers LF, Jeffers LJ, Abu-Elmagd K, Connor J, et al. Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology. 2006;130:1643–1651. doi: 10.1053/j.gastro.2006.02.008. [DOI] [PubMed] [Google Scholar]
  19. Hou MC, Lin HC, Liu TT, Kuo BI, Lee FY, Chang FY, Lee SD, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology. 2004;39:746–753. doi: 10.1002/hep.20126. [DOI] [PubMed] [Google Scholar]
  20. Jutabha R, Jensen D, et al. Management of upper gastrointestinal bleeding in patients with chronic liver disease. Med Clin Noth Am. 1996;80:1035–1068. doi: 10.1016/s0025-7125(05)70479-x. [DOI] [PubMed] [Google Scholar]
  21. Krige JE, Kotze UK, Bornman PC, Shaw JM, Klipin M, et al. Variceal recurrence, rebleeding, and survival after endoscopic injection sclerotherapy in 287 alcoholic cirrhotic patients with bleeding esophageal varices. Ann Surg. 2006;244:764–770. doi: 10.1097/01.sla.0000231704.45005.4e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lata J, Hulek P, Vanasek T, et al. Management of acute variceal bleeding. Dig Dis. 2003;21:6–15. doi: 10.1159/000071333. [DOI] [PubMed] [Google Scholar]
  23. Lo G, Lai K, Cheng J, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology. 2000;32:461–465. doi: 10.1053/jhep.2000.16236. [DOI] [PubMed] [Google Scholar]
  24. Lo G, Chen W, Chen M, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal bleeding. Gastroenterology. 2002;123:728–734. doi: 10.1053/gast.2002.35351. [DOI] [PubMed] [Google Scholar]
  25. Luca A, D’Amico G, LaGalla R, et al. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis for randomized clinical trials. Radiology. 1999;212:411–421. doi: 10.1148/radiology.212.2.r99au46411. [DOI] [PubMed] [Google Scholar]
  26. Matloff D, et al. Treatment of acute variceal bleeding. Gastrenterol Clin North Am. 1992;21:103–118. [PubMed] [Google Scholar]
  27. Orloff MJ, Isenberg JI, Wheeler HO, Haynes KS, Jinich-Brook H, Rapier R, Vaida F, Hye RJ, et al. Randomized trial of emergency endoscopic sclerotherapy versus emergency portacaval shunt for acutely bleeding esophageal varices in cirrhosis. J Am Coll Surg. 2009;209:25–40. doi: 10.1016/j.jamcollsurg.2009.02.059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Papatheodoridis G, Goulis J, Leandro G, et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding. Hepatology. 1999;30:612–622. doi: 10.1002/hep.510300316. [DOI] [PubMed] [Google Scholar]
  29. Patch D, Sabin C, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for tye prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology. 2002;123:1013–1019. doi: 10.1053/gast.2002.35955. [DOI] [PubMed] [Google Scholar]
  30. Rodriguez-Perez F, Groszmann R, et al. Pharmacologic treatment of portal hypertension. Gastroenterol Clin North Am. 1992;21:15–40. [PubMed] [Google Scholar]
  31. Rosemurgy AS, Zervos EE, Bloomston M, Durkin AJ, Clark WC, Goff S, et al. Post-shunt resource consumption favors small-diameter prosthetic H-graft portacaval shunt over TIPS for patients with poor hepatic reserve. Ann Surg. 2003;237:820–825. doi: 10.1097/01.SLA.0000072102.38993.05. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Rössle M, Grant D, et al. TIPS: an update. Best Practice & Res Clin Gastroenterol. 2004;18:99–123. doi: 10.1016/j.bpg.2003.08.004. [DOI] [PubMed] [Google Scholar]
  33. Ryan BM, Stockbrugger RW, Ryan JM, et al. A pathophysiologic, gastroenterologic, and radiologic approach to the management of gastric varices. Gastroenterology. 2004;126:1175–1189. doi: 10.1053/j.gastro.2004.01.058. [DOI] [PubMed] [Google Scholar]
  34. Sarin S, Jain A, Gupta R, et al. A randomized controlled trial of cynoacrylate versus alcohol injection in patients with isolated fundus varices. Am J Gastroenterol. 2002;97:1010–1015. doi: 10.1111/j.1572-0241.2002.05622.x. [DOI] [PubMed] [Google Scholar]
  35. Stiegmann G, Goff J, Sun J, et al. Endoscopic elastic band ligation for active variceal hemorrhage. Am Surg. 1989;55:124–128. [PubMed] [Google Scholar]
  36. Stipa S, Balducci G, Ziparo V, et al. Total shunting and elective management of variceal bleeding. World J Surg. 1994;18:200–204. doi: 10.1007/BF00294401. [DOI] [PubMed] [Google Scholar]
  37. Thalheimer U, Mela M, Patch D, Burroughs A, et al. Targeting portal pressure measurements: A critical reappraisal. Hepatology. 2004;39:286–290. doi: 10.1002/hep.20061. [DOI] [PubMed] [Google Scholar]
  38. Villanueva C, Colomo A, Aracil C, Guarner C, et al. Current endoscopic therapy of variceal bleeding. Best Pract Res Clin Gastroenterol. 2008;22:261–278. doi: 10.1016/j.bpg.2007.11.012. [DOI] [PubMed] [Google Scholar]
  39. Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared worth combined treatment with nadolol and isosorbide mononitrate tomprevent recurrent variceal bleeding. N Engl J Med. 2001;345:647–655. doi: 10.1056/NEJMoa003223. [DOI] [PubMed] [Google Scholar]
  40. Vinel J, Lamouliatte H, Cales P, et al. Propanolol reduces the rebleeding rate during endoscopic sclerotherapy before variceal obliteration. Gastroenterology. 1992;102:1760–1763. doi: 10.1016/0016-5085(92)91740-u. [DOI] [PubMed] [Google Scholar]
  41. Warren W, Zeppa R, Fomon J, et al. Selective transsplenic decompression of gastroesophageal varices by distal splenorenal shunt. Ann Surg. 1967;166:437–455. doi: 10.1097/00000658-196709000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]

38.3.2 Literatur

  1. Ahboucha S, Pomier-Layrargues G, Butterworth RF, et al. Increased brain concentrations of endogenous (non-benzodiazepine) GABA-A receptor ligands in human hepatic encephalopathy. Metab Brain Dis. 2004;19:241–251. doi: 10.1023/b:mebr.0000043974.89820.22. [DOI] [PubMed] [Google Scholar]
  2. Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002;36:1367–1373. doi: 10.1053/jhep.2002.36947. [DOI] [PubMed] [Google Scholar]
  3. Bosch J, Abraldes JG, et al. Variceal bleeding:pharmacological therapy. Dig Dis. 2005;23:18–29. doi: 10.1159/000084722. [DOI] [PubMed] [Google Scholar]
  4. Burroughs AK, et al. Prevention of variceal bleeding. Gastroenterol Clin North Am. 1992;21:119–147. [PubMed] [Google Scholar]
  5. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt : Correlation with hemodynamic findings. Gastroenterology. 1998;114:1296–1303. doi: 10.1016/s0016-5085(98)70436-6. [DOI] [PubMed] [Google Scholar]
  6. Castano G, Viudez P, Riccitelli M, et al. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients. Ann Hepatol. 2003;2:36–40. [PubMed] [Google Scholar]
  7. Chalasani N, Boyer TD, et al. Primary prophylaxis against variceal bleeding: beta-blockers, endoscopic ligation, or both? Am J Gastroenterol. 2005;100:805–807. doi: 10.1111/j.1572-0241.2005.41855.x. [DOI] [PubMed] [Google Scholar]
  8. Escorsell A, Ferayorni L, Bosch J, et al. The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology. 1997;112:2012–2016. doi: 10.1053/gast.1997.v112.pm9178694. [DOI] [PubMed] [Google Scholar]
  9. Fernandez M, Meijas M, Angermayr B, et al. Inhibition of VEGF receptor-2 decreases the developent of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005;43:98–103. doi: 10.1016/j.jhep.2005.02.022. [DOI] [PubMed] [Google Scholar]
  10. Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of reccurrent variceal haemorrhage in patients with cirrhosis. Lancet. 1995;346:1056–1059. doi: 10.1016/s0140-6736(95)91740-3. [DOI] [PubMed] [Google Scholar]
  11. Fiorucci S, Antonelli E, Morelli O, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA. 2001;98:8897–8902. doi: 10.1073/pnas.151136298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Garcia-Pagan JC, Morillas R, Banares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-moninitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology. 2003;37:1260–1266. doi: 10.1053/jhep.2003.50211. [DOI] [PubMed] [Google Scholar]
  13. Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985;5:419–424. doi: 10.1002/hep.1840050313. [DOI] [PubMed] [Google Scholar]
  14. Gentile S, Guarine G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol. 2005;3:184–191. doi: 10.1016/s1542-3565(04)00667-6. [DOI] [PubMed] [Google Scholar]
  15. Gimson AE, Ramage JK, Panos MZ, et al. Randomised trial of variceal banding ligation versus injection slerotherapy for bleeding oesophageal varices. Lancet. 1993;342:391–394. doi: 10.1016/0140-6736(93)92812-8. [DOI] [PubMed] [Google Scholar]
  16. Groszmann RJ, Glickman M, Blei AT, et al. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology. 1979;76:253–258. [PubMed] [Google Scholar]
  17. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990;99:1401–1407. doi: 10.1016/0016-5085(90)91168-6. [DOI] [PubMed] [Google Scholar]
  18. Groszmann RJ, Garcia-Tsao G, Makuch R, et al. Multicenter, randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor. Hepatology. 2003;38(1):206A. [Google Scholar]
  19. Gyr K, Meier R, Haussler J, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double-blind, radomised, placebo-controlled multicentre study. Gut. 1996;39:319–324. doi: 10.1136/gut.39.2.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hayes PC, Davis JM, Lewis JA, et al. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet. 1990;336:153–156. doi: 10.1016/0140-6736(90)91668-z. [DOI] [PubMed] [Google Scholar]
  21. Hernandez-Guerra M, Garcia-Pagan JC, Bosch J, et al. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol. 2005;39(2):S131–S137. doi: 10.1097/01.mcg.0000155513.17715.f7. [DOI] [PubMed] [Google Scholar]
  22. Jutabha R, Jensen DM, Martin P, et al. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology. 2005;128:870–881. doi: 10.1053/j.gastro.2005.01.047. [DOI] [PubMed] [Google Scholar]
  23. Lo GH, Chen WC, Wang HM, et al. Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices. Gut. 2009;58(9):1275–1280. doi: 10.1136/gut.2008.165910. [DOI] [PubMed] [Google Scholar]
  24. Maddrey WC, et al. Role of antibiotics in the management of hepatic encephalopathy. Rev Gastroenterol Disord. 2005;5(1):3–9. [PubMed] [Google Scholar]
  25. Marchesini G, Marzocchi R, Noia M, et al. Branched-chain amino acid supplementation in patients with liver dieseases. J Nutr. 2005;135(6):1596S–1601S. doi: 10.1093/jn/135.6.1596S. [DOI] [PubMed] [Google Scholar]
  26. Pagliaro L, Burroughs AK, Sorensen TIA, et al. Therapeutic controversies and randomised controlled trials (RCTs): prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int. 1989;2:71–84. [Google Scholar]
  27. Perello A, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virusrelated cirrhosis. Hepatology. 1999;30:1393–1397. doi: 10.1002/hep.510300628. [DOI] [PubMed] [Google Scholar]
  28. Perez-Ayuso RM, Pique JM, Bosch J, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet. 1991;337:1431–1434. doi: 10.1016/0140-6736(91)93125-s. [DOI] [PubMed] [Google Scholar]
  29. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med. 1991;324:1532–1538. doi: 10.1056/NEJM199105303242202. [DOI] [PubMed] [Google Scholar]
  30. Sarin SK, Groszmann RJ, Mosca PG, et al. Propranolol ameliorates the development of portal-systemic shunting in chronic murine schistosomiasis model of portal hypertension. J Clin Invest. 1991;87:1032–1036. doi: 10.1172/JCI115062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sarin SK, Wadhawan M, Gupta R, et al. Evaluation of endoscopic variceal ligation (EVL) versus propranolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirhotic patients. Dig Dis Sci. 2005;50:1538–1547. doi: 10.1007/s10620-005-2877-1. [DOI] [PubMed] [Google Scholar]
  32. Schepke M, Kleber G, Nürnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2004;40:65–72. doi: 10.1002/hep.20284. [DOI] [PubMed] [Google Scholar]
  33. Soehendra N, Grimm H, Nam VC, et al. N-butyl-2-cyanoacrylate: a supplement to endoscopic sclerotherapy. Endoscopy. 1987;19:221–224. doi: 10.1055/s-2007-1018288. [DOI] [PubMed] [Google Scholar]
  34. Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med. 1992;326:1527–1532. doi: 10.1056/NEJM199206043262304. [DOI] [PubMed] [Google Scholar]
  35. Sumanovski LT, Battegay E, Stumm M, et al. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology. 1999;29:1044–1049. doi: 10.1002/hep.510290436. [DOI] [PubMed] [Google Scholar]
  36. Therapondos G, Ferguson JW, Newby DE, et al. Endothelin-1 contributes to the maintenance of systemic hemodynamics in patients with cirrhosis: A double-blind randomized controlled hemodynamic study. Hepatology. 2004;40(1):185A. [Google Scholar]
  37. Tripathi D, Therapondos G, Lui HF, et al. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol. 2004;99:390–394. doi: 10.1111/j.1572-0241.2004.04051.x. [DOI] [PubMed] [Google Scholar]
  38. Viallet A, Marleau D, Huet M, et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology. 1975;69:1297–130. [PubMed] [Google Scholar]
  39. Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with scelrotherapy for the prevention of variceal rebleeding. N Engl J Med. 1996;334:11624–11629. doi: 10.1056/NEJM199606203342502. [DOI] [PubMed] [Google Scholar]
  40. Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent reccurent variceal bleeding. N Engl J Med. 2001;345:647–655. doi: 10.1056/NEJMoa003223. [DOI] [PubMed] [Google Scholar]
  41. Vorobioff J, Groszmann RJ, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: A 10-year prospective study. Gastroenterology. 1996;111:701–709. doi: 10.1053/gast.1996.v111.pm8780575. [DOI] [PubMed] [Google Scholar]
  42. Wongcharatrawee S, Groszmann RJ, et al. Diagnosing portal hypertension. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:881–894. doi: 10.1053/bega.2000.0136. [DOI] [PubMed] [Google Scholar]
  43. Zeneroli ML, Avallone R, Corsi L, et al. Management of hepatic encephalopathy: role of rifaximin. Chemotherapy. 2005;51(1):90–95. doi: 10.1159/000081994. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Benoit JNGD, et al. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis. 1986;6:287–98. doi: 10.1055/s-2008-1040611. [DOI] [PubMed] [Google Scholar]
  2. Bosch JMR, Kravetz D, et al. Hemodynamic evaluation of the patients with portal hypertension. Semin Liver Dis. 1986;6:309–317. doi: 10.1055/s-2008-1040613. [DOI] [PubMed] [Google Scholar]
  3. Childs C, et al. Eck’s fistula. Surg Gynecol Obstet. 1953;96:375–376. [Google Scholar]
  4. Clavien PA, Selzner M, Tuttle-Newhall JE, et al. Liver transplantation complicated by misplaced TIPS in the portal vein. Ann Surg. 1998;227(3):440–445. doi: 10.1097/00000658-199803000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Colbas JC, et al. Narrow diameter portacaval shunt for the management of variceal bleeding. W J Surg. 1994;18:211–215. doi: 10.1007/BF00294403. [DOI] [PubMed] [Google Scholar]
  6. Coldwell DRE, Rees CR, et al. Multicenter investigation of the role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Rad. 1995;196:335–340. doi: 10.1148/radiology.196.2.7617842. [DOI] [PubMed] [Google Scholar]
  7. Collins JCRE, Sarfeh IJ, et al. Narrow-diameter portacaval shunt for management of variceal bleeding. W J Surg. 1994;70:211–215. doi: 10.1007/BF00294403. [DOI] [PubMed] [Google Scholar]
  8. Ginsberg RJWP, Strasberg SM, et al. The Sugiura procedure for bleeding esophageal varices: modification. Can J Surg. 1982;25(3):325–339. [PubMed] [Google Scholar]
  9. Hahn MMO, Nencki M, Pavlov J, et al. Die Eck’sche Fistel zwischen der unteren Hohlvene and der Pfortader und ihre Folgen für den Organismus. Arch Exp Pathol Pharmokol. 1893;32:162–210. [Google Scholar]
  10. Henderson JMGT, Hooks MA, et al. Selective shunt in the management of variceal bleeding in the era of liver transplantation. Ann Surg. 1992;216(3):248–255. doi: 10.1097/00000658-199209000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Henderson JMMW, Wright-Bacon L, et al. Hemodynamic differences between alcoholic and non-alcoholic cirrhotic following distal splenorenal shunt. Ann Surg. 1983;198:325. doi: 10.1097/00000658-198309000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klein AS, et al. Diagnosis and management of the Budd-Chiari syndrome. Am J Surg. 1990;160:128–133. doi: 10.1016/s0002-9610(05)80882-7. [DOI] [PubMed] [Google Scholar]
  13. Lillemoe KD, et al. The interposition mesocaval shunt. Surg Clinic N Am. 1990;70:379–394. doi: 10.1016/s0039-6109(16)45087-5. [DOI] [PubMed] [Google Scholar]
  14. Orloff MJ, et al. The biliary system. In: Sabiston DS, et al., editors. Textbook of surgery. 10th. Philadelphia: Saunders; 1972. p. 1009. [Google Scholar]
  15. Orloff MJ, Greenberg AG, et al. Prospective randomized trial of emergency portacaval shunts and medical therapy in unselected cirrhotic patients with bleeding varices. Gastro. 1986;90:1754. doi: 10.1002/hep.1840200414. [DOI] [PubMed] [Google Scholar]
  16. Orozco HMM, Takahashi T, Hernandez-Ortiz, Capellan JF, Garcia-Tsao G, et al. Elective treatment of bleeding varices with the Sugiura operation over 10 years. Am J Surg. 1992;163:585–589. doi: 10.1016/0002-9610(92)90562-6. [DOI] [PubMed] [Google Scholar]
  17. Pugh RNH, Dawson JL, et al. Transsection of the oesophagael varices. Br J Surg. 1973;60:646–664. doi: 10.1002/bjs.1800600817. [DOI] [PubMed] [Google Scholar]
  18. Rikkers L, et al. Bleeding esophageal varices. Surg Clinics NA. 1987;67:475–488. doi: 10.1016/s0039-6109(16)44227-1. [DOI] [PubMed] [Google Scholar]
  19. Rikkers L, et al. Definitive therapy for variceal bleeding: a personal view. Am J Surg. 1990;160:80–85. doi: 10.1016/s0002-9610(05)80873-6. [DOI] [PubMed] [Google Scholar]
  20. Rosemurgy AS, Bloomston M, et al. H-graft portacaval shunts versus TIPS; ten-year follow-up of a randomized trial with comparison to predicted survivals. Ann Surg. 2005;241(2):238–46. doi: 10.1097/01.sla.0000151884.67600.b6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rössle MHK, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. New Engl J Med. 1994;330:165–171. doi: 10.1056/NEJM199401203300303. [DOI] [PubMed] [Google Scholar]
  22. Sarfeh IJ, et al. Partial versus total portacaval shunt in alcoholic cirrhosis: results of a prospective randomized clinical trial. Ann Surg. 1994;219:352–361. doi: 10.1097/00000658-199404000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Skeens JSC, Dake M, et al. Transjugular intrahepatic portosystemic shunts. Ann Rev Med. 1995;46:95–102. doi: 10.1146/annurev.med.46.1.95. [DOI] [PubMed] [Google Scholar]
  24. Sugiura M, et al. A new technique for treating esophageal varices. J Thorac Cardiovasc Surg. 1973;66:677. [PubMed] [Google Scholar]
  25. Sugiura M, Futagawa S, et al. Further evaluation of the Sugiura procedure in the treatment of esophageal varices. Arch Surg. 1977;112:1317. doi: 10.1001/archsurg.1977.01370110051005. [DOI] [PubMed] [Google Scholar]
  26. Sugiura M, Futagawa S, et al. Esophageal transection with paraesophagogastric devascularizations (the Sugiura procedure) in the treatment of esophageal varices. World J Surg. 1984;8:673. doi: 10.1007/BF01655762. [DOI] [PubMed] [Google Scholar]
  27. Warren WD, Henderson JM, et al. Ten years’ portal hypertensive surgery at Emory. Ann Surg. 1982;195:530. doi: 10.1097/00000658-198205000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wexler MJ, et al. Treatment of bleeding esophageal varices by transabdominal esophaegeal transection with the EEA stapling instrument. Surgery. 1980;88(3):406. [PubMed] [Google Scholar]

38.4.2 Literatur

  1. Arroyo V, Clària J, Salò J, et al. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis. 1994;24:44–54. doi: 10.1055/s-2007-1007297. [DOI] [PubMed] [Google Scholar]
  2. D’Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic factors in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31:468–485. doi: 10.1007/BF01320309. [DOI] [PubMed] [Google Scholar]
  3. Deltenre P, Mathurin P, Dharancy S, et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver International. 2005;25:349. doi: 10.1111/j.1478-3231.2005.01095.x. [DOI] [PubMed] [Google Scholar]
  4. Fernández-Esparrach G, Guevara M, Sort P, et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol. 1997;26:614–620. doi: 10.1016/s0168-8278(97)80427-8. [DOI] [PubMed] [Google Scholar]
  5. García-Pagán JV, Salmerón JM, Feu F, et al. Effects of low- sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology. 1994;19:1095–1099. doi: 10.1002/hep.1840190506. [DOI] [PubMed] [Google Scholar]
  6. Gauthier A, Levy VG, Quinton H, et al. Salt or no salt in the treatment of cirrhotic ascites: a randomized study. Gut. 1986;27:705–709. doi: 10.1136/gut.27.6.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gerbes AL, Bertheau-Reitha U, Falkner C, et al. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites – a randomized, double-blind crossover trial. J Hepatol. 1993;17:353–358. doi: 10.1016/s0168-8278(05)80217-x. [DOI] [PubMed] [Google Scholar]
  8. Ginés A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111:1002–1010. doi: 10.1016/s0016-5085(96)70068-9. [DOI] [PubMed] [Google Scholar]
  9. Ginés P, Arroyo V, Quintero E, et al. Comparison of parancentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology. 1987;93:234–241. doi: 10.1016/0016-5085(87)91007-9. [DOI] [PubMed] [Google Scholar]
  10. Ginés P, Arroyo V, Rodés J, et al. Pharmacotherapy of ascites associated with cirrhosis. Drugs. 1992;43:317–332. doi: 10.2165/00003495-199243030-00003. [DOI] [PubMed] [Google Scholar]
  11. Ginés P, Guevara M, et al. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology. 2008;48:1002–1010. doi: 10.1002/hep.22418. [DOI] [PubMed] [Google Scholar]
  12. Ginés P, Jiménez W, et al. Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. J Hepatol. 1996;24:506–512. doi: 10.1016/s0168-8278(96)80174-7. [DOI] [PubMed] [Google Scholar]
  13. Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7:122–128. doi: 10.1002/hep.1840070124. [DOI] [PubMed] [Google Scholar]
  14. Ginés P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12:716–724. doi: 10.1002/hep.1840120416. [DOI] [PubMed] [Google Scholar]
  15. Inadomi J, Sonnengerg A, et al. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology. 1997;113:1289–1294. doi: 10.1053/gast.1997.v113.pm9322524. [DOI] [PubMed] [Google Scholar]
  16. Laffi G, Marra F, Buzzelli G, et al. Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study. Hepatology. 1991;13:1101–1105. [PubMed] [Google Scholar]
  17. Nevens F, Lijnen P, Van Billoen H, et al. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology. 1996;23:1047–1052. doi: 10.1053/jhep.1996.v23.pm0008621132. [DOI] [PubMed] [Google Scholar]
  18. Pérez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites – relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology. 1983;83:961–968. [PubMed] [Google Scholar]
  19. Pockros PJ, Reynolds TB, et al. Rapid diuresis in patients with ascites from chronic liver disease. the importance of peripheral edema Gastroenterology. 1986;90:1827–1833. doi: 10.1016/0016-5085(86)90249-0. [DOI] [PubMed] [Google Scholar]
  20. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and longterm prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology. 1995;22:1171–1174. doi: 10.1016/0270-9139(95)90626-6. [DOI] [PubMed] [Google Scholar]
  21. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Int Med. 1992;117:215–220. doi: 10.7326/0003-4819-117-3-215. [DOI] [PubMed] [Google Scholar]
  22. Saab S, Nieto JM, Ly D, Runyon BA, et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites (review) Cochrane Database Syst Rev. 2004;3:CD004889. doi: 10.1002/14651858.CD004889. [DOI] [PubMed] [Google Scholar]
  23. Salerno F, Badalamenti S, Incerti P, et al. Repeat paracentesis and iv albumin infusion to treat »tense« ascites in cirrhotic patients: a safe alternative therapy. J Hepatol. 1987;5:102–108. doi: 10.1016/s0168-8278(87)80067-3. [DOI] [PubMed] [Google Scholar]
  24. Shear L, Ching S, Gabuzda GJ, et al. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med. 1970;282:1391–1396. doi: 10.1056/NEJM197006182822502. [DOI] [PubMed] [Google Scholar]
  25. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and saftey. J Hepatol. 2003;39:187–192. doi: 10.1016/s0168-8278(03)00188-0. [DOI] [PubMed] [Google Scholar]
  26. Sherlock S, Senewiratne B, Scott A et al. (1966) Complications of diuretic therapy in hepatic cirrhosis. Lancet i:1049–1053 [DOI] [PubMed]
  27. Singh N, Gayowski T, Yu VL, et al. Trimethoprim-sufamethoxazole for the prevention od spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Int Med. 1995;122:595–598. doi: 10.7326/0003-4819-122-8-199504150-00007. [DOI] [PubMed] [Google Scholar]
  28. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409. doi: 10.1056/NEJM199908053410603. [DOI] [PubMed] [Google Scholar]
  29. Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satvaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010;53:283–290. doi: 10.1016/j.jhep.2010.02.036. [DOI] [PubMed] [Google Scholar]

38.4.4 Literatur

  1. Arroyo V, Gines P, Planas R, et al. Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis. Gastroenterol Clin North Am. 1992;21:237–256. [PubMed] [Google Scholar]
  2. Clara R, Righi D, Bortolini M, Cornaglia S, Ruffino MA, Zanon C, et al. Role of different techniques for the placement of Denver peritoneovenous shunt (PVS) in malignant ascites. Surg Laparoscop Endoscop Percutan Tech. 2004;14:222–225. doi: 10.1097/01.sle.0000136675.54624.16. [DOI] [PubMed] [Google Scholar]
  3. Edney JA, Hill A, Armstrong D, et al. Peritoneovenous shunts palliate malignant ascites. Am J Surg. 1989;158:598–601. doi: 10.1016/0002-9610(89)90202-x. [DOI] [PubMed] [Google Scholar]
  4. Elcheroth J, Vons C, Franco D, et al. Role of surgical therapy in management of intractable scites. World J Surg. 1994;18:240–245. doi: 10.1007/BF00294408. [DOI] [PubMed] [Google Scholar]
  5. Ferral H, Bjarnason H, Wegryn SA, Rengel GJ, Nazarian GK, Rank JM, Tadavarthy SM, Hunter DW, Castaneda-Zuniga WR, et al. Refractory ascites: Early experience in treatment with transjugular intrahepatic portosystemic shunt. Radiology. 1993;189:795–801. doi: 10.1148/radiology.189.3.8234706. [DOI] [PubMed] [Google Scholar]
  6. Feussner H, Siewert JR, et al. Chirurgische Maßnahmen bei therapieresistentem Aszites. In: Siewert JR, Harder F, Allgöwer M, Blum AL, Hollender LF, Peiper HJ, et al., editors. Chirurgische Gastroenterologie. Berlin: Springer; 1990. [Google Scholar]
  7. Fulenwider JT, Galambos JD, Smith RB, Henderson JM, Warren WD, et al. LeVeen vs Denver peritoneovenous shunts for intractable ascites of cirrhosis. A randomized, prospective trial. Arch Surg. 1986;121:351–355. doi: 10.1001/archsurg.1986.01400030113018. [DOI] [PubMed] [Google Scholar]
  8. Gines A, Planas R, Angeli P, Guarner C, Salerno F, Gines P, Salo J, Rodriguez N, Domenech E, Soriano G, et al. Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: comparison with therapeutic paracentesis. Hepatology. 1995;22:124–131. doi: 10.1002/hep.1840220120. [DOI] [PubMed] [Google Scholar]
  9. Gough IR, Balderson GA, et al. Malignant ascites. A comparison of peritoneovenous shunting and nonoperative management. Cancer. 1993;71:2377–2388. doi: 10.1002/1097-0142(19930401)71:7<2377::aid-cncr2820710732>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  10. Henderson JM, Barnes DS, Geisinger MA, et al. Ascites. Curr Probl Surg. 1998;35:435–438. [PubMed] [Google Scholar]
  11. Hillaire S, Labianca M, Borgonovo G, Smadja C, Grange D, Franco D, et al. Peritoneovenous shunting of intractable ascites in patients with cirrhosis: improving results and predictive factors of failure. Surgery. 1993;113:373–379. [PubMed] [Google Scholar]
  12. LeVeen HH, Christoudias G, Ip M, Luft K, Falk G, Grosberg S, et al. Peritoneovenous shunting for ascites. Ann Surg. 1974;180:580–590. doi: 10.1097/00000658-197410000-00023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rosemurgy AS, Statman RC, Murphy CG, Albrink MH, McAllister EW, et al. Postoperative ascitic leaks:The ongoing challenge. Surgery. 1992;111:623–625. [PubMed] [Google Scholar]
  14. Schölmerich J, et al. Strategies in the treatment of ascites. Hepato-Gastroenterol. 1991;38:365–370. [PubMed] [Google Scholar]
  15. Schumacher DL, Saclarides TJ, Staren ED, et al. Peritoneovenous shunts for palliation of the patient with malignant ascites. Ann Surg Oncol. 1994;1:378–381. doi: 10.1007/BF02303809. [DOI] [PubMed] [Google Scholar]
  16. Schumpelick V, Riesener KP, et al. Peritoneo-venöser Shunt – Indikation, Grenzen, Ergebnisse. Chirurg. 1993;64:11–15. [PubMed] [Google Scholar]
  17. Zanon C, Grosso M, Apra F, Clara R, Bortolini M, Quaglino F, Cornaglio S, Simone P, et al. Palliative treatment of malignant refractory ascites by positioning of Denver peritoneovenous shunt. Tumori. 2002;88:123–127. doi: 10.1177/030089160208800208. [DOI] [PubMed] [Google Scholar]
  18. Zühlke H, Häring R, et al. Therapie des Aszites – chirurgisch. In: Paquet KJ, Schölmerich J, et al., editors. Pfortaderhochdruck. Basel: Karger; 1994. [Google Scholar]

Articles from Praxis der Viszeralchirurgie. Gastroenterologische Chirurgie are provided here courtesy of Nature Publishing Group

RESOURCES